The Dermatology Digest

FEBRUARY 18, 2025

Just days after snagging dual approvals for moderate-to-severe atopic dermatitis (AD) and prurigo nodularis (PN) in the European Union, nemolizumab (Nemluvio, Galderma) was also granted Marketing Authorization in the United Kingdom (UK) and Switzerland for AD and PN.

Dermatitis 36

Dermatitis Marketing Hospital Clinic 36

The Dermatology Digest

DECEMBER 14, 2023

Ofir Cohn PhD , Boston Children’s Hospital, Boston, MA Deciphering how genetic variation associated with risk of eczema impacts human dendritic cell subset function Liwen Deng BS, PhD , President & Fellows of Harvard College, Boston, MA S.

Eczema 36

Eczema Dermatitis Hospital Networking 36

The Dermatology Digest

JANUARY 14, 2024

The overwhelming majority of people with atopic dermatitis (AD) treated with investigational roflumilast cream 0.15% (Zoryve, Arcutis) showed a measurable improvement in Eczema Area and Severity Index (EASI) in 4 weeks, according to new pooled analyses from two Phase 3 studies. Fully 91.5%

Dermatitis 36

Dermatitis Safety Dermatology Hospital 36

The Dermatology Digest

JANUARY 30, 2024

The 2023 PeDRA Research Grant recipients are: Joyce Teng, MD, PhD of Stanford University, will conduct a project titled “ A Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of a Hypertonic Gel in the Treatment of Pediatric Cutaneous Pyogenic Granuloma.

Partnerships 36

Partnerships Eczema Hospital Dermatology 36

The Dermatology Digest

MARCH 11, 2024

Sanofi’s investigational OX40-ligand blocker amlitelimab produces sustained improvement in the signs and symptoms of atopic dermatitis (AD) in adults who previously responded and continued treatment and sustained off-drug improvements in those who stopped treatment.

Sustainability 36

Sustainability Dermatitis Safety Hospital 36

The Beauty Brains

OCTOBER 17, 2016

According to Fisher’s Contact Dermatitis, acne can result from topical application of cosmetic products via two mechanisms. There’s a rating scale published by ARPANSA which stands for Australian Radiation Protection and Nuclear Safety Agency. That’s a great question but patch testing for acne does NOT work.

Sun Protection 40

Sun Protection Extractions Ingredients Comedogenic 40

The Dermatology Digest

FEBRUARY 24, 2025

improved atopic dermatitis (AD) across all primary and secondary efficacy endpoints, with significant improvement as early as Week 1 on multiple efficacy endpoints in kids aged 2 to 5, according to the INTEGUMENT-PED Trial. Roflumilast cream 0.05% (Zoryve, Arcutis Biotherapeutics, Inc.) As previously reported, at Week 4, 25.4% of patients.

Eczema 67

Eczema Dermatitis Safety Dermatology 67